248 related articles for article (PubMed ID: 28946014)
1. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Strickler JH; Wu C; Bekaii-Saab T
Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
[TBL] [Abstract][Full Text] [Related]
2. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in BRAF-mutant metastatic colorectal cancer.
Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
[TBL] [Abstract][Full Text] [Related]
4. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
5. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
[TBL] [Abstract][Full Text] [Related]
6. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
7. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
8. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Lee HM; Morris V; Napolitano S; Kopetz S
Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
[TBL] [Abstract][Full Text] [Related]
9. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.
Temraz S; Alameddine R; Shamseddine A
Curr Opin Oncol; 2015 May; 27(3):276-81. PubMed ID: 25774859
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
Davis LE
Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
13. Current and future targets and therapies in metastatic colorectal cancer.
Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
[TBL] [Abstract][Full Text] [Related]
14. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
15. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Johnson B; Kopetz S
Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
[TBL] [Abstract][Full Text] [Related]
16. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
[TBL] [Abstract][Full Text] [Related]
18. BRAF testing in advanced colorectal cancer: is it ready for prime time?
Phillips B; Kalady M; Kim R
Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
[TBL] [Abstract][Full Text] [Related]
19. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.
Sanz-Garcia E; Argiles G; Elez E; Tabernero J
Ann Oncol; 2017 Nov; 28(11):2648-2657. PubMed ID: 29045527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
